Facente Consulting supported Gilead Sciences with statistical analysis relating to HIV incidence rates, assisting with the study design, analysis plan, and interpretation of study data for the PURPOSE trials–ultimately leading to the groundbreaking FDA approval of the twice-yearly PrEP medication Lenacapavir.